Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 46.8 Cr.
- Current Price ₹ 40.0
- High / Low ₹ 159 / 38.2
- Stock P/E 19.5
- Book Value ₹ 23.3
- Dividend Yield 0.00 %
- ROCE 16.6 %
- ROE 19.9 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.4% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 241 days.
- Working capital days have increased from 179 days to 252 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
31.49 | 25.05 | 20.98 | 22.15 | 25.27 | |
30.14 | 23.41 | 19.78 | 20.29 | 20.53 | |
Operating Profit | 1.35 | 1.64 | 1.20 | 1.86 | 4.74 |
OPM % | 4.29% | 6.55% | 5.72% | 8.40% | 18.76% |
0.09 | 0.01 | 0.21 | 0.82 | 0.02 | |
Interest | 0.46 | 0.48 | 0.47 | 0.61 | 0.65 |
Depreciation | 0.77 | 0.68 | 0.68 | 0.71 | 0.72 |
Profit before tax | 0.21 | 0.49 | 0.26 | 1.36 | 3.39 |
Tax % | 47.62% | 40.82% | 61.54% | 28.68% | 28.91% |
0.10 | 0.30 | 0.09 | 0.97 | 2.40 | |
EPS in Rs | 0.17 | 0.50 | 0.15 | 1.62 | 2.79 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 0% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 100% |
TTM: | 147% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
Last Year: | 20% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 6.00 | 6.00 | 6.00 | 6.00 | 8.60 | 11.70 |
Reserves | 1.11 | 1.47 | 1.56 | 2.98 | 6.58 | 15.61 |
8.27 | 9.59 | 10.24 | 11.79 | 12.66 | 12.88 | |
10.44 | 9.28 | 9.27 | 11.82 | 10.75 | 8.80 | |
Total Liabilities | 25.82 | 26.34 | 27.07 | 32.59 | 38.59 | 48.99 |
11.28 | 11.35 | 11.29 | 10.87 | 10.35 | 10.39 | |
CWIP | 0.06 | 0.00 | 0.00 | 0.00 | 0.15 | 0.15 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
14.48 | 14.99 | 15.78 | 21.72 | 28.09 | 38.45 | |
Total Assets | 25.82 | 26.34 | 27.07 | 32.59 | 38.59 | 48.99 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
1.58 | -1.16 | 0.04 | -0.58 | -3.69 | |
-0.45 | -0.02 | -0.59 | -0.28 | -0.33 | |
-0.55 | 1.27 | 0.18 | 0.94 | 4.01 | |
Net Cash Flow | 0.58 | 0.09 | -0.37 | 0.07 | -0.01 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 63.98 | 109.72 | 108.73 | 177.47 | 241.21 |
Inventory Days | 101.47 | 61.22 | 128.47 | 225.01 | 244.39 |
Days Payable | 225.45 | 161.56 | 198.97 | 329.82 | 281.81 |
Cash Conversion Cycle | -60.01 | 9.38 | 38.24 | 72.66 | 203.80 |
Working Capital Days | 34.66 | 83.35 | 121.61 | 163.30 | 251.61 |
ROCE % | 5.98% | 4.19% | 10.22% | 16.62% |
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
15 January 2025 - Medicamen Organics Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
15 January 2025 - Medicamen Organics Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
15 January 2025 - Medicamen Organics Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q3 FY 2024-25
-
Alteration Of Capital and Fund Raising-XBRL
13 January 2025 - MEDICAMEN ORGANICS LIMITED has informed regarding Issuance of securities
-
Copy of Newspaper Publication
13 January 2025 - Medicamen Organics Limited has informed about Copy of Newspaper Publication
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.